Indications to teriparatide treatment in patients with osteoporosis.

Details

Ressource 1Download: BIB_8E9C85377252.P001.pdf (573.49 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_8E9C85377252
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Indications to teriparatide treatment in patients with osteoporosis.
Journal
Swiss Medical Weekly
Author(s)
Rizzoli R., Kraenzlin M., Krieg M.A., Mellinghoff H.U., Lamy O., Lippuner K.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
2011
Volume
141
Pages
w13297
Language
english
Abstract
To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide treatment reduces vertebral and non-vertebral fracture risk markedly in women and men with idiopathic osteoporosis, or with glucocorticoid-induced osteoporosis. Teriparatide should thus be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.
Pubmed
Web of science
Open Access
Yes
Create date
01/12/2011 14:07
Last modification date
20/08/2019 14:52
Usage data